Takeaways: Health Canada’s approval of Fasenra for hypereosinophilic syndrome (HES) gives Canadian patients a much‑needed, evidence‑backed option that can cut flare‑ups and improve fatigue, potentiall...
Takeaways: The Canadian approval of Besremi gives PharmaEssentia a new, targeted therapy in the chronic myeloproliferative neoplasm space, expanding its hematology/oncology footprint beyond Taiw...
Takeaways Hemgenix has moved from theory to practice in Canada, with the first patient now treated outside a trial and public funding in place in Ontario and British Columbia. Market‑wise, this...
Takeaways Blenrep’s pCPA negotiations are an important step toward broader Canadian access to a new multiple myeloma option, especially because the drug is being positio...
